INDV · Indivior Pharmaceuticals Inc
United States · RS rating 54 · As of 2026-10-14
| Price | 34.16 USD |
|---|---|
| 1-day change | -3.6% |
| RS rating (overall / 1M / 3M / 12M) | 54 / 67 / 24 / 87 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 47 / 42 / 58 |
| Industry group (rank) | Medical-Ethical Drugs (91) |
| EPS growth Q/Q | +139.4% |
| Sales growth Q/Q | +14.0% |
| Distance from 52-week high | +18.3% |
| Market cap (USD) | $4.0B |